Broadwood Partners, L.P. Buys 21,155 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 21,155 shares of the business’s stock in a transaction on Tuesday, January 14th. The shares were bought at an average cost of $21.46 per share, for a total transaction of $453,986.30. Following the acquisition, the insider now owns 10,869,786 shares of the company’s stock, valued at $233,265,607.56. This represents a 0.20 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The stock was bought at an average cost of $21.50 per share, with a total value of $176,751.50.
• On Wednesday, December 18th, Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock. The shares were purchased at an average cost of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. bought 53,500 shares of STAAR Surgical stock. The stock was purchased at an average cost of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Trading Up 2.0 %

Shares of STAA stock opened at $22.29 on Friday. The company has a market capitalization of $1.10 billion, a P/E ratio of 50.66 and a beta of 0.63. The business’s 50 day moving average is $25.38 and its two-hundred day moving average is $31.92. STAAR Surgical has a twelve month low of $21.13 and a twelve month high of $52.68.

Hedge Funds Weigh In On STAAR Surgical

A number of hedge funds and other institutional investors have recently bought and sold shares of STAA. Arcadia Investment Management Corp MI purchased a new position in STAAR Surgical during the 3rd quarter worth $37,000. Quarry LP acquired a new position in shares of STAAR Surgical during the third quarter worth about $50,000. Canada Pension Plan Investment Board acquired a new position in shares of STAAR Surgical during the second quarter worth about $129,000. Quest Partners LLC purchased a new position in STAAR Surgical during the third quarter worth about $128,000. Finally, Van ECK Associates Corp lifted its position in STAAR Surgical by 12.7% in the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 393 shares during the period. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on STAA. Stephens raised STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Canaccord Genuity Group cut their target price on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, December 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $42.83.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.